Ferring Pharmaceuticals AS is in pole position to be first pharmaceutical company to file a treatment that harnesses the power of the human microbiome, with a potential launch pencilled in next year for RBX2660 for reducing recurrent Clostridioides difficile (C diff) infection in adults.
The privately owned Swiss firm, best known for its reproductive medicines, has made the microbiome a key element of its...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
